Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

PURPOSE: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enric...

Descripción completa

Detalles Bibliográficos
Autores principales: Boni, Valentina, Fidler, Mary J., Arkenau, Hendrik-Tobias, Spira, Alexander, Meric-Bernstam, Funda, Uboha, Nataliya, Sanborn, Rachel E., Sweis, Randy F., LoRusso, Patricia, Nagasaka, Misako, Garcia-Corbacho, Javier, Jalal, Shadia, Harding, James J., Kim, Stella K., Miedema, Iris H.C., Vugts, Danielle J., Huisman, Marc C., Zwezerijnen, Gerben J.C., van Dongen, Guus A.M.S., Menke van der Houven van Oordt, C. Willemien, Wang, Song, Dang, Tam, Zein, Ivan A., Vasiljeva, Olga, Lyman, Susan K., Paton, Virginia, Hannah, Alison, Liu, Joyce F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365353/
https://www.ncbi.nlm.nih.gov/pubmed/35165101
http://dx.doi.org/10.1158/1078-0432.CCR-21-3656

Ejemplares similares

Ejemplares similares